Appropriate dose of tranexamic acid in the topical treatment of anterior epistaxis, 500 mg vs 1000 mg: A double-blind randomized controlled trial
Science Progress · 2024
DOI: 10.1177/00368504241264993 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Science Progress, 2024. Verfasst von Cüneyt Arikan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, İzmir Ataturk Training and Research Hospital, Izmir, Turkey. Hauptthemen laut MEDLINE: Tranexamic Acid, Epistaxis, Administration, Topical, Antifibrinolytic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Patients with epistaxis typically visit the emergency department for initial treatment. According to recent studies, tranexamic acid (TXA) is effective in the treatment of epistaxis. This study compared the therapeutic superiority of saline to that of 500 and 1000 mg doses of topical TXA for the treatment of anterior epistaxis. Materials and methods: This phase 4 clinical trial was a randomized, controlled, and double-blind trial. A total of 152 patients were divided into three groups. Group 1 was treated with 1000 mg TXA, Group 2 with 500 mg TXA, and Group 3 with saline.
Results
Based on multinomial logistic regression analysis, the bleeding frequency at the 5th minute was 2.9 times and rebleeding status was 4.3 times less in Group 1 (1000 mg TXA) than in Group 3 (saline). There were no differences between the three groups in terms of side effects or salvage therapy.
Conclusion
In addition to its superiority in treatment, 1000 mg of TXA is recommended because of the decreased rate of recurrent bleeding and low incidence of side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, İzmir Ataturk Training and Research Hospital, Izmir, Turkey.
- Department of Emergency Medicine, Soma State Hospital, Manisa, Turkey.
ORCID-Profile: Cüneyt Arikan, Pınar Yeşim Akyol
Zitieren
APA
Arikan, C., & Akyol, P. Y. (2024). Appropriate dose of tranexamic acid in the topical treatment of anterior epistaxis, 500 mg vs 1000 mg: A double-blind randomized controlled trial. Science Progress. https://doi.org/10.1177/00368504241264993
Vancouver
Arikan C, Akyol PY. Appropriate dose of tranexamic acid in the topical treatment of anterior epistaxis, 500 mg vs 1000 mg: A double-blind randomized controlled trial. Science Progress. 2024. doi:10.1177/00368504241264993
BibTeX
@article{Arikan2024,
author = {Arikan, Cüneyt and Akyol, Pınar Yeşim},
title = {Appropriate dose of tranexamic acid in the topical treatment of anterior epistaxis, 500 mg vs 1000 mg: A double-blind randomized controlled trial},
journal = {Science Progress},
year = {2024},
doi = {10.1177/00368504241264993}
}
EUVIMED